HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011

[1]  A. Vincent-Salomon,et al.  [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. , 2010 .

[2]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[3]  Manfred Dietel,et al.  HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing , 2010, Virchows Archiv.

[4]  H. Kreipe,et al.  Her2-Diagnostik beim Magenkarzinom , 2010, Der Pathologe.

[5]  G. Sauter,et al.  HER-2 amplification is highly homogenous in gastric cancer. , 2010, Human pathology.

[6]  M. J. van de Vijver,et al.  Emerging technologies for assessing HER2 amplification. , 2009, American journal of clinical pathology.

[7]  Dong Xu,et al.  Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer , 2009, World Journal of Surgery.

[8]  E. Van Cutsem,et al.  Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[10]  T. Henkel,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[11]  F. Penault-Llorca,et al.  Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification , 2007, Breast Cancer Research.

[12]  K. Mori,et al.  Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[13]  E. Cho,et al.  HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer , 2006, Digestive Diseases and Sciences.

[14]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[15]  S. Kitano,et al.  Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. , 2005, International journal of oncology.

[16]  J. Isola,et al.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  D. Rimm,et al.  Long-term preservation of antigenicity on tissue microarrays , 2004, Laboratory Investigation.

[18]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  A. Martín,et al.  Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer , 2003, Annals of Surgical Oncology.

[20]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Yano,et al.  Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. , 2006, Oncology reports.

[23]  M. Sobrinho-Simões,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 2000, Cancer.

[24]  Copyright © American Society for Investigative Pathology Review Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids , 2022 .